OBJECTIVES: To seek cerebral metabolite abnormalities in patients with myotonic dystrophy and to determine whether the degree of cerebral abnormalities (measured by proton magnetic resonance spectroscopy) correlates with severity of the genetic defect (measured by trinucleotide repeats). DESIGN: Fourteen patients with myotonic dystrophy were compared with 24 healthy control subjects. SETTING: A university-affiliated medical center. RESULTS: Compared with healthy subjects, patients with myotonic dystrophy had elevated levels of myoinositol (+19% in the occipital region and +12.9% in the temporoparietal region), total creatine (+7.6% and +6.8%), and choline-containing compounds (+21% and +7.7%). Furthermore, the creatine and myoinositol peak areas correlated with the number of trinucleotide cytosine-thymine-guanine(n) (CTG)n repeats from leukocytes, especially in the temporoparietal brain region (r=0.76; P=.004). CONCLUSIONS: Neurochemical alterations observed with proton magnetic resonance spectroscopy are proportional to the cytosine-thymine-guanine repeat size. Increases in myoinositol and creatine concentrations may be caused by increased glial content, while elevated levels of choline-containing compounds are most likely caused by increased glial content and cell membrane abnormalities. Proton magnetic resonance spectroscopy is a powerful noninvasive tool to study brain biochemistry, which may reflect the extent of neuropathological involvement in patients with myotonic dystrophy.
OBJECTIVES: To seek cerebral metabolite abnormalities in patients with myotonic dystrophy and to determine whether the degree of cerebral abnormalities (measured by proton magnetic resonance spectroscopy) correlates with severity of the genetic defect (measured by trinucleotide repeats). DESIGN: Fourteen patients with myotonic dystrophy were compared with 24 healthy control subjects. SETTING: A university-affiliated medical center. RESULTS: Compared with healthy subjects, patients with myotonic dystrophy had elevated levels of myoinositol (+19% in the occipital region and +12.9% in the temporoparietal region), total creatine (+7.6% and +6.8%), and choline-containing compounds (+21% and +7.7%). Furthermore, the creatine and myoinositol peak areas correlated with the number of trinucleotide cytosine-thymine-guanine(n) (CTG)n repeats from leukocytes, especially in the temporoparietal brain region (r=0.76; P=.004). CONCLUSIONS:Neurochemical alterations observed with proton magnetic resonance spectroscopy are proportional to the cytosine-thymine-guanine repeat size. Increases in myoinositol and creatine concentrations may be caused by increased glial content, while elevated levels of choline-containing compounds are most likely caused by increased glial content and cell membrane abnormalities. Proton magnetic resonance spectroscopy is a powerful noninvasive tool to study brain biochemistry, which may reflect the extent of neuropathological involvement in patients with myotonic dystrophy.
Authors: Damien Galanaud; S Haik; M G Linguraru; J-P Ranjeva; B Faucheux; E Kaphan; N Ayache; J Chiras; P Cozzone; D Dormont; J-P Brandel Journal: AJNR Am J Neuroradiol Date: 2010-04-29 Impact factor: 3.825
Authors: J Suhy; R G Miller; R Rule; N Schuff; J Licht; V Dronsky; D Gelinas; A A Maudsley; M W Weiner Journal: Neurology Date: 2002-03-12 Impact factor: 9.910
Authors: J Suhy; W D Rooney; D E Goodkin; A A Capizzano; B J Soher; A A Maudsley; E Waubant; P B Andersson; M W Weiner Journal: Mult Scler Date: 2000-06 Impact factor: 6.312
Authors: R Lodi; J M Cooper; J L Bradley; D Manners; P Styles; D J Taylor; A H Schapira Journal: Proc Natl Acad Sci U S A Date: 1999-09-28 Impact factor: 11.205
Authors: Vincenzo Romeo; E Pegoraro; F Squarzanti; G Sorarù; C Ferrati; M Ermani; P Zucchetta; F Chierichetti; C Angelini Journal: Neurol Sci Date: 2010-09-15 Impact factor: 3.307
Authors: Paul M Macey; Manoj K Sarma; Janani P Prasad; Jennifer A Ogren; Ravi Aysola; Ronald M Harper; M Albert Thomas Journal: Neuroscience Date: 2017-09-08 Impact factor: 3.590
Authors: Hannah M Kersten; Richard H Roxburgh; Nicholas Child; Philip J Polkinghorne; Chris Frampton; Helen V Danesh-Meyer Journal: J Neurol Date: 2013-10-17 Impact factor: 4.849